Fig 1: Effects of iPS-ML-41BBL against MO4 melanoma in vivo. (A) The model of treatment schedule; luciferase-expressing MO4 cells are intraperitoneally injected into B6-albino mice (1.0 × 106 cells/mouse). After 5 days, the mice were randomly divided into control (n = 8), OVA peptide-pulsed iPS-ML (n = 8), and OVA peptide-pulsed iPS-ML-41BBL (n = 8) treatment groups. The mice in the OVA peptide-pulsed iPS-ML or OVA peptide-pulsed iPS-ML-41BBL groups were injected with 1 × 107 cells/mouse/injection on days 5–10 and 12–17. (B) Luminescence images showing tumor growth. (C) Plots showing fold change in tumor-associated luminescence from day 5. (D) The Kaplan-Meier plot of the overall survival and median survival time (MST). * p < 0.05. (E) Infiltration of T cells into MO4 melanoma tissues. The treatment and sampling schedule are the same as shown in Figure 2A. The immunofluorescence staining was analyzed using a fluorescence microscope BZ-X700. T cell marker CD3 was stained by Alexa Fluor 488. FCM analysis of dissociated cells obtained from tumor tissues harvested on day 18. (F) The sampling schedule is the same as that shown in Figure 1C. Effects of iPS-ML expressing CXCL16 on no cells, iPS-ML, and iPS-ML-41BBL. Expression levels of CXCL16 were analyzed using ELISA. n.s. = not significant, * p < 0.05.
Supplier Page from Abcam for Mouse CXCL16 ELISA Kit